In a study recently published in Cell Reports Medicine, a team of researchers lead by senior author Dr. Randy Longman, Director of the Jill Roberts Center for IBD and Associate Professor of Medicine at Weill Cornell Medicine in the Division of Gastroenterology & Hepatology, examined IBD-SpA patients treated with sulfasalazine and found that the presence of the gut bacterium Faecalibacterium prausnitzii was a key factor enabling successful treatment responses. They determined that...
A new study lead by Weill Department of Medicine and NewYork-Presbyterian investigators finds that certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives the disease while also causing long-term immune system changes. This discovery also identifies a group of patients who may benefit from specialized, but yet-to-be determined treatments.The research reveals a new dimension of the...
Dr. Gregory F. Sonnenberg, The Henry R. Erle, M.D.-Roberts Family Associate Professor of Medicine and head of basic research in the division of Gastroenterology and Hepatology in the Weill Department of Medicine, has been awarded a $3.26 million, five-year MERIT grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to investigate the underlying causes of inflammatory bowel disease (IBD).The new grant, which has the...
Coinciding with National Nurses Week, Shentique Brown, RN, was among the recipients of Weill Cornell Medicine’s first annual nursing awards. Shentique, a nurse in the division of Gastroenterology & Hepatology, received the first annual Rising Star Nursing Award at a ceremony May 11 in the Belfer Research Building.“It’s...
Dr. Brandman aims to expand the existing care models for liver transplant patients with alcohol related liver disease and nonalcoholic fatty liver disease, as well as to improve outreach efforts to patients with advanced liver disease.
Dr. Artis and team continue to illuminate the role of ILC2s, a family of white blood cells, with a new discovery published in Nature that has resolved an ongoing controversy.
As reported in Cell, these pain-sensing neurons protect against inflammation in the gut as well as the associated tissue damage, apparently by secreting a molecule called substance P.
The breakthrough research holds promise for developing diagnostic tests for the prediction of cancer progression and therapy.
Building upon his laboratory’s many discoveries centered around ILC3s, Dr. Gregory Sonnenberg has published another breakthrough in Nature (September 7, 2022).
This five-year, $1.25 million grant will enable Dr. Iliev to continue his innovative research into the relationship between certain types of fungi and specific cancers.
